Innovus Pharmaceuticals Inc. (fka INNV)

[kkpennies]

$INNV INNOVUS PHARMA (OTCMKTS:INNV) Shorted Shares Increased By 59.91%

http://presstelegraph.com/2016/08/31/innovus-pharma-otcmktsinnv-shorted-shares-increased-by-59-91/

The stock of INNOVUS PHARMA (OTCMKTS:INNV) registered an increase of 59.91% in short interest. INNV’s total short interest was 960,400 shares in August as published by FINRA. Its up 59.91% from 600,600 shares, reported previously. With 2.67 million shares average volume, it will take short sellers 0 days to cover their INNV’s short positions. The stock decreased 4.71% or $0.014 on August 30, hitting $0.283. About 3.14M shares traded hands or 56.22% up from the average. Innovus Pharmaceuticals Inc (OTCMKTS:INNV) has risen 559.67% since January 27, 2016 and is uptrending. It has outperformed by 544.10% the S&P500.

Innovus Pharmaceuticals, Inc. is a pharmaceutical firm engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The company has a market cap of $30.08 million. The Firm markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It currently has negative earnings. It has commercial agreements in over 60 countries around the world through its commercial partners.

The information provided on this website is for individual use only and should be considered strictly informational in nature. The article is not advice, and should not be treated as such. We are in no way responsible for any investment loss or damages. All content in our articles is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities.

Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our articles. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. We make no recommendation that the securities of the companies profiled or discussed in on our website should be purchased, sold or held by investors.